LSD's short but colorful history in North America carries with it the distinct cachet of counterculture and government experimentation. The truth about this mind-altering chemical cocktail is far more complex—and less controversial—than generally believed. Psychedelic Psychiatry is the tale of medical researchers working to understand LSD’s therapeutic properties just as escalating anxieties about drug abuse in modern society laid the groundwork for the end of experimentation at the edge of psychopharmacology. Historian Erika Dyck deftly recasts our understanding of LSD to show it as an experimental substance, a medical treatment, and a tool for exploring psychotic perspectives—as well as a recreational drug. She recounts the inside story of the early days of LSD research in small-town, prairie Canada, when Humphry Osmond and Abram Hoffer claimed incredible advances in treating alcoholism, understanding schizophrenia and other psychoses, and achieving empathy with their patients. In relating the drug’s short, strange trip, Dyck explains how concerns about countercultural trends led to the criminalization of LSD and other so-called psychedelic drugs—concordantly opening the way for an explosion in legal prescription pharmaceuticals—and points to the recent re-emergence of sanctioned psychotropic research among psychiatric practitioners. This challenge to the prevailing wisdom behind drug regulation and addiction therapy provides a historical corrective to our perception of LSD’s medical efficacy.

A recent wave of research in psychiatry and neuroscience has re-examined the properties of “classic” psychedelic substances - also known as serotonergic hallucinogens - such as psilocybin, LSD, and DMT. Evidence to date suggests that psychedelics can be given safely in controlled conditions, at moderate to high doses, and may have potential as therapeutic agents in the treatment of various addictive and mood disorders. The main mechanism of action appears to be the induction of a dramatically altered state of consciousness, but the details of how psychedelic-assisted psychotherapy works are hotly debated, as are the relations between psychedelic experiences themselves and the neural changes induced by the drugs. Philosophical Perspectives on Psychedelic Psychiatry addresses the fascinating philosophical questions raised by the renewed psychiatric use of psychedelics, with chapters from leading philosophers of mind, science, and psychiatry centred around three main themes. Chapters in the “self and mind” section ask: what can we learn about the self and the mind from psychedelic science? Chapters in the “science and psychiatry” section address methodological, theoretical, and clinical questions concerning how psychedelics can best be studied scientifically and used therapeutically, and how they might work to relieve psychiatric suffering. Finally, chapters in the “ethics and spirituality” section address broader questions about the interpretation of psychedelic experience, its ethical implications, and its possible role(s) in the broader culture.

There is substantial contemporary interest in psychedelic agents as medicines for maladies of the mind. This follows research in the 1950s and 1960s exploring the use of LSD and other psychedelics to treat a range of psychiatric illnesses as well as addictions. This research was shut down after prohibition of these drugs, however the last decade has seen a major renewal of interest in the therapeutic use of psychedelics and related drugs in psychiatry. Psilocybin (found in 'magic mushrooms') has been used effectively for amelioration of distress in people with depression/anxiety in the context of potentially life-ending cancers, as well as for treatment-resistant depression and also addictions. MDMA ('ecstasy') has shown efficacy for severe post-traumatic stress disorder, with enduring benefit. Other psychedelics, both plant-derived (e.g., ayahuasca) and synthetically produced (e.g., LSD) are also being investigated for their potential therapeutic value. These agents not only herald a new neurobiology but also allow an integration of psychotherapy with biological compounds that is truly novel and that challenges established psychiatric practice. Furthermore, the action of these agents on the brain allows an exploration of how the brain works to 'open up' to psychotherapeutic healing. Published as part of the Oxford Psychiatry Library series, the book provides an overview of this hugely exciting field, covering the history of psychedelics, clinical aspects, risks and side effects, precautions and processes.

Integral Psychedelic Therapy is a groundbreaking, evidence-based collection that explores how psychedelic medicine can be incorporated into contemporary psychotherapy. This book builds on current psychedelic research by providing an in-depth articulation of the practice of psychedelic therapy, weaving together a variety of complementary therapeutic frameworks, case examples, and practical guidance for cultivating a highly effective, ethically grounded, integral approach. Chapters by a diverse set of practicing psychotherapists and leading researchers aim to provide practitioners with a method that centers liberation of all dimensions of being through intersectional, client-centered, trauma-informed, and attachment-focused practices, alongside thoughtful attunement to the relational, somatic, imaginal, cultural, and transpersonal dimensions of healing. Integral Psychedelic Therapy will be essential reading for psychotherapists in practice and in training as well as those seeking personal healing and holistic transformation.

The post-World War II era was a tumultuous period in the world of psychiatry. Medical history has cast it as a clash between biology and psychoanalysis or as a time that lacked objectivism, that is until the introduction of psychotropic drugs such as chlorpromazine which triggered a change in our treatment of mental health as profound and far-reaching in its consequences as the war itself. In the early years of this psychopharmacological revolution, hallucinogens such as mescaline and LSD played as much of a role as other psychotropics. In fact, psychedelics constituted a scientific revolution in their own right, one that does not however fit the narrative of twentieth century scientific history. Looking beyond the countercultural manifestations and references that have for decades obfuscated the psychedelic story, historian P.W. Barber delves into a serious examination of both the science and the people behind the research. Showing why and how this experimentation unfolded, what its findings were and how these findings were received both within and outside the scientific community, Psychedelic Revolutionaries completely resets a long-misunderstood history by following the work of three pioneering psychiatrists - Humphry Osmond, who coined the term 'psychedelic' and administered Aldous Huxley his first dose of mescaline, Abram Hoffer and Duncan Blewett, also known as the 'Leary of the North'. While considering how it is that scientific discoveries become accepted as established truths, Barber invites us to ask: what is it that makes a scientific discovery revolutionary?

EMBARK Psychedelic Therapy for Depression: A New Approach for the Whole Person represents a critical step forward in the field of psychedelic therapy. The book is a comprehensive guide for clinicians, offering a groundbreaking therapeutic framework for administering psychedelic medicines in treating depression. Developed in response to identified gaps in existing models of psychedelic therapy, the EMBARK model addresses the need for a comprehensive, ethical, and inclusive approach. It bridges gaps from previous psychedelic therapies, such as lack of attentiveness to the body and rigorous ethical practice. EMBARK offers a transdiagnostic and trans-drug approach adaptable to various indications and psychedelic medicines. It's built on four Cornerstones of Care: Trauma-Informed Care, Culturally Competent Care, Ethically Rigorous Care, and Collective Care, reflecting the belief that efficacious treatment is ethical treatment. The EMBARK acronym represents six Clinical Domains that commonly emerge for people in psychedelic experiences: Existential-Spiritual, Mindfulness, Body Aware, Affective-Cognitive, Relational, and Keeping Momentum. The book provides practical instructions and suggested agendas for therapists, and offers a flexible, participant-centric approach to integration, focusing on the clinical domains that emerged for the participant. It also links theory to practice for the treatment of depression, drawing from twelve proposed psychological mechanisms of therapeutic change in psychedelic therapy, and provides a comprehensive guide to treatment factors. EMBARK psychedelic therapy is open-sourced to the clinical community for development and adaptation to other psychedelic medicines, diverse populations, and to inform the development of psychedelic practitioner trainings, making it an essential resource for those interested in the field of psychedelic therapy.

The co-operative spirit of citizens in twentieth-century Saskatchewan nurtured innovation in health care and health policy. 36 Steps on the Road to Medicare showcases the decisions that led to the province's medicare system - the forerunner of Canadian health care. Stuart Houston and Merle Massie document the range of Saskatchewan leadership on Canadian, North American, and world stages: municipal doctors and municipal hospitals, the first Red Cross Outpost Hospital in the British Empire, tuberculosis diagnosis and treatment, a successful pilot comprehensive regional health care plan, government-sponsored cancer clinics, innovative LSD and patient-oriented treatment for psychoses, the first full-time cancer physicist in Canada, and the world's first concerted clinical use of the betatron and Cobalt-60 in cancer treatment. They show how North America's first social-democratic government, the Co-operative Commonwealth Federation - elected in 1944 and led by the incomparable Tommy Douglas - created the blueprint for comprehensive health care and how sequential steps on the road to medicare were implemented quickly and within budget. When federal support for national hospitalization became available, Saskatchewan could afford to initiate medicare in 1962. Other Canadian provinces soon followed Saskatchewan's lead. Updated to engage with current debates, 36 Steps on the Road to Medicare navigates the history of medicare and demonstrates the spirit of innovation that Canada will need to save it.

Psychedelic compounds use has a rich and complicated history spanning through ancient cultures, modern medical use, cultural movements and national and international politics. With the latest resurgence of use of these compounds in mental health and medical conditions, we are just scratching the surface of understanding the mechanisms that underlie these drugs' effects and their ways of action in the single body and in society as a whole.

Seattle has a long tradition of being at the forefront of technological innovation. In 1919, an eager young inventor named Alfred M. Hubbard made his first newspaper appearance with the announcement of a perpetual motion machine that harnessed energy from Earth's atmosphere. From there, Hubbard transformed himself into a charlatan, bootlegger, radio pioneer, top-secret spy, millionaire and uranium entrepreneur. In 1953, after discovering the transformative effects of a little-known hallucinogenic compound, Hubbard would go on to become the "Johnny Appleseed of LSD," introducing the psychedelic to many of the era's vanguards and an entire generation. Join author and historian Brad Holden as he chronicles the fascinating life of one of Seattle's legendary figures.